CompletedEUCTR 2006-002682-40
Augmenting clozapine with sertindole - A double-blinded randomized placebo study (SERCLOZ)
This historical record does not confirm current site availability.
Historical research recordDenmarkSchizophrenia
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Denmark
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 50
- Sponsor
- Aalborg Psychiatric Hospital, Research Unit
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Denmark
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2006-002682-40
- Official title
Show the full official title
Augmenting clozapine with sertindole - A double-blinded randomized placebo study (SERCLOZ)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Denmark
Registry details
Historical country statuses
- Denmark — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Aalborg Psychiatric Hospital, Research Unit, a hospital or academic medical center.
Want to explore more studies?
Explore studiesRelated studies
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni...